Aaron Kantoff

Insider Reports History

Location
C/O Centessa Pharmaceuticals Plc, D. Hodgkin Bldg, Babraham Rsrch Campus, Cambridge, United Kingdom
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Aaron Kantoff:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Tourmaline Bio, Inc. Director Common Stock 93.3K $882K $9.46 Sep 5, 2025 Direct
Centessa Pharmaceuticals plc Director Ordinary Shares 60K $478K $7.96 Nov 18, 2021 Direct
Avalo Therapeutics, Inc. Director Restricted Stock Units 6.33K $53.6K $8.46 Mar 28, 2025 Direct
Avalo Therapeutics, Inc. Director Common Stock 3.17K $26.8K $8.46 Mar 28, 2025 Direct
Avalo Therapeutics, Inc. Director Stock Option (Right to Buy) 20.1K Jun 17, 2025 Direct
Tourmaline Bio, Inc. Director Stock Option (Right to Buy) 0 Sep 5, 2025 Direct

Insider Reports Filed by Aaron Kantoff

Symbol Company Period Transactions Value $ Form Type Date Filed Role
TRML Tourmaline Bio, Inc. Sep 5, 2025 4 $99.5K 4 Sep 9, 2025 Director
AVTX Avalo Therapeutics, Inc. Jun 17, 2025 1 $0 4 Jun 18, 2025 Director
TRML Tourmaline Bio, Inc. Jun 4, 2025 1 $0 4 Jun 6, 2025 Director
AVTX Avalo Therapeutics, Inc. Mar 28, 2025 2 $0 4 Apr 1, 2025 Director
AVTX Avalo Therapeutics, Inc. Aug 13, 2024 2 $0 4 Aug 14, 2024 Director
TRML Tourmaline Bio, Inc. Jun 5, 2024 1 $0 4 Jun 7, 2024 Director
AVTX Avalo Therapeutics, Inc. Mar 28, 2024 0 $0 3 Apr 3, 2024 Director
TALS Tourmaline Bio, Inc. Oct 24, 2023 1 $89K 4 Oct 26, 2023 Director
TALS Tourmaline Bio, Inc. Oct 19, 2023 3 $0 4 Oct 23, 2023 Director
TALS Tourmaline Bio, Inc. Oct 19, 2023 0 $0 3 Oct 23, 2023 Director
CNTA Centessa Pharmaceuticals plc Nov 18, 2021 1 $120K 4 Nov 18, 2021 Director
CNTA Centessa Pharmaceuticals plc May 27, 2021 0 $0 3 May 27, 2021 Director